Cure8 research brief
The study found disease-specific antibody changes years before IBD diagnosis, suggesting possible early biomarkers and new clues about how Crohn's disease and ulcerative colitis begin.
Researchers studying IBD pathogenesis or biomarkers, clinicians interested in early detection of IBD, and translational teams working on serologic tests.
The research profiled antibody repertoires against hundreds of thousands of peptides in longitudinal US military samples from people who later developed CD or UC and matched controls.
Increased antibody repertoire variability appeared up to ~4 years before diagnosis; some antibody signals (anti-flagellin, Epstein–Barr virus–directed responses) were detectable up to 10 years before diagnosis in pre-CD, while responses to certain encapsulated bacteria declined toward diagnosis.
These results are based on large-scale serological profiling of archived samples and reveal candidate preclinical biomarkers and immune patterns that could inform future studies of early detection or pathogenesis.
This paper reports an abstract-level summary from the journal (Gut); Cure8 did not independently verify raw data or downstream clinical performance of the proposed markers.
Findings derive from high-throughput PhIP-Seq profiling of archived military cohort sera; the published abstract summarizes associations and trajectories but does not establish a validated predictive clinical test.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Competing interests: The corresponding author confirms on behalf of all authors that there have been no involvements that might raise the question of bias in the work reported or in the conclusions, implications or opinions stated. SM reports receiving research grants from Genentech and Takeda; receiving payment for lectures from Takeda, Genentech, Morphic; and receiving consulting fees from Takeda, Morphic, Ferring and Arena Pharmaceuticals. ARB reports receiving research grants from Janssen Pharmaceuticals and received speaker’s fees from Ferring and AbbVie. SG reports other research funding from Genentech, Boehringer-Ingelheim, EMD Serono, Takeda and Regeneron. JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals, Takeda and Bristol Myers Squibb; receiving payment for lectures from AbbVie and Takeda; receiving consulting fees from AbbVie, Amgen, AnaptysBio, Allergan, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Celltrion, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Genentech (Roche), Janssen Pharmaceuticals, Kaleido Biosciences, Immunic, Invea, Iterative Scopes, Merck, Landos, Microba Life Science, Novartis, Nautilus, Otsuka Pharmaceutical, Pfizer, Protagonist Therapeutics, Prometheus, Sanofi, Seres, Takeda, Teva, TiGenix, Vifor and hold stock options in Intestinal Biotech Development. All other authors have no conflicts of interest to declare.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
The study suggests measurable retinal and choroidal microvascular differences in people with IBD versus controls, which could point to systemic vascular effects of inflammation and offer noninvasive biomarker...
The work identifies a genetic link (HLA‑DRB1*01:03) to anti‑IL‑10 autoantibodies and describes a small subgroup of IBD patients who may have a distinct immune mechanism driving disease—information that could matter for...
